Search results
Biotechnology company ProQR has announced that two of its RNA therapy development programmes for inherited sight loss are being acquired by Laboratoires Théa, a company specialising in eye care products.
Back for 2023, the virtual TCS London Marathon lets you join our team close to home and get your marathon medal!
Sign up to receive regular updates from Retina UK and learn more about the most innovative research and technology news, upcoming events, fundraising and support services available.
In 2023, the annual Isle of Wight walk in support of Retina UK will return. Starting at Ryde Pier, walkers will follow a five mile scenic walk with spectacular views.
Take on a challenge with #TeamRetinaUK! Run, jog or walk 10 miles in your neighbourhood.
This webinar covers key questions and topic areas including what Usher syndrome is, how to get a diagnosis, both clinical and genetic, and what will happen after this.
Our first Expert is Simon Keightley, a consultant ophthalmic surgeon and Director of Examinations for the International Council of Opthalmology. With more than 35 years in the field, Simon is ready and waiting for your questions.
Retina UK has a number of online support resources which we offer via social media.
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
